MX2024004141A - Formulación farmacéutica inyectable de liberación sostenida de levotiroxina y proceso para la preparación de la misma. - Google Patents

Formulación farmacéutica inyectable de liberación sostenida de levotiroxina y proceso para la preparación de la misma.

Info

Publication number
MX2024004141A
MX2024004141A MX2024004141A MX2024004141A MX2024004141A MX 2024004141 A MX2024004141 A MX 2024004141A MX 2024004141 A MX2024004141 A MX 2024004141A MX 2024004141 A MX2024004141 A MX 2024004141A MX 2024004141 A MX2024004141 A MX 2024004141A
Authority
MX
Mexico
Prior art keywords
levothyroxine
preparation
sustained release
pharmaceutical formulation
injectable pharmaceutical
Prior art date
Application number
MX2024004141A
Other languages
English (en)
Spanish (es)
Inventor
Evangelos Karavas
Efthymios Koutris
Sotiria Chaitidou
Lida Kalantzi
Nikos Lemonakis
Anna Papadaki
Vincent Brieudes
Artemis Kalezi
Athanasios Katsenis
Katerina Kotti
Original Assignee
Pharmathen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20210100683A external-priority patent/GR1010327B/el
Priority claimed from GB2119164.8A external-priority patent/GB2613656A/en
Application filed by Pharmathen Sa filed Critical Pharmathen Sa
Publication of MX2024004141A publication Critical patent/MX2024004141A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024004141A 2021-10-06 2022-10-06 Formulación farmacéutica inyectable de liberación sostenida de levotiroxina y proceso para la preparación de la misma. MX2024004141A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR20210100683A GR1010327B (el) 2021-10-06 2021-10-06 Παρατεταμενης αποδεσμευσης ενεσιμο φαρμακευτικο σκευασμα λεβοθυροξινης και μεθοδος παρασκευης αυτου
GB2119164.8A GB2613656A (en) 2021-12-13 2021-12-13 Sustained release injectable pharmaceutical formulation of levothyroxine and process for preparation thereof
PCT/EP2022/025463 WO2023057088A1 (en) 2021-10-06 2022-10-06 Sustained release injectable pharmaceutical formulation of levothyroxine and process for preparation thereof

Publications (1)

Publication Number Publication Date
MX2024004141A true MX2024004141A (es) 2024-07-10

Family

ID=83996642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004141A MX2024004141A (es) 2021-10-06 2022-10-06 Formulación farmacéutica inyectable de liberación sostenida de levotiroxina y proceso para la preparación de la misma.

Country Status (10)

Country Link
US (1) US20250268830A1 (https=)
EP (1) EP4412594A1 (https=)
JP (1) JP2024536419A (https=)
KR (1) KR20240066197A (https=)
AU (1) AU2022360328A1 (https=)
CA (1) CA3234073A1 (https=)
CO (1) CO2024005798A2 (https=)
MX (1) MX2024004141A (https=)
WO (1) WO2023057088A1 (https=)
ZA (1) ZA202403411B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4701631A1 (en) * 2023-04-28 2026-03-04 Maia Pharmaceuticals, Inc. Levothyroxine dispersions
CN116831994B (zh) * 2023-06-25 2026-03-27 湖南赛隆药业(长沙)有限公司 一种注射用左甲状腺素钠缓释微球冻干制剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127634A (zh) 1995-04-06 1996-07-31 中国科学院成都有机化学研究所 一种激素缓释微球注射剂及其制备方法
CN113384537A (zh) * 2021-04-25 2021-09-14 苏州大学 一种左旋千金藤啶碱缓释微球及其制备方法

Also Published As

Publication number Publication date
US20250268830A1 (en) 2025-08-28
CA3234073A1 (en) 2023-04-13
AU2022360328A1 (en) 2024-05-16
JP2024536419A (ja) 2024-10-04
CO2024005798A2 (es) 2024-05-10
WO2023057088A1 (en) 2023-04-13
ZA202403411B (en) 2025-01-29
EP4412594A1 (en) 2024-08-14
KR20240066197A (ko) 2024-05-14

Similar Documents

Publication Publication Date Title
CO2024005798A2 (es) Formulación farmacéutica inyectable de liberación sostenida de levotiroxina y proceso para la preparación de la misma
DOP2017000162A (es) Forma de dosificación que incluye una solución sólida de drogas amorfas
AR134222A2 (es) Un proceso para preparar una composición de comprimido adecuada para el tratamiento de trastornos mediados por la actividad de la tirosina cinasa de bruton
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
BR112012023324B8 (pt) processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
NO20073722L (no) Farmasoystiske sammensetniger omfattende bendamustin
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
MX394644B (es) Excipiente a base de proteínas para ingredientes farmacéuticos activos.
MX2018008050A (es) Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada.
NO20082988L (no) Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer
MX2015014656A (es) Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.
MX387266B (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos
MX2016012846A (es) Preparacion de microesferas de plga cargadas de peptido con caracteristicas de liberacion controlada.
BR112014009438A2 (pt) composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral
CO6640305A2 (es) Elaboración de gránulos sin activos y tabletas que comprenden los mismos
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
CY1122113T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου
PY1929301A (es) Formulación sólida de mezclas insecticidas.-
CY1125375T1 (el) Ενα λυοφιλοποιημενο φαρμακευτικο σκευασμα και η χρηση του
CO6190600A2 (es) Metodo para formar una tableta que comprende el premezclado de ibuprofeno y silice
CY1119542T1 (el) Προϊον μικρονισμου που περιλαμβανει οξεικη ουλιπρισταλη
MY159789A (en) Octreotide depot formulation with constantly high exposure levels
BR112015001640A2 (pt) formulações e métodos de produção de formulações para uso em evacuação colônica
BR112014032583A2 (pt) forma farmacêutica para liberação prolongada de substâncias ativas